BORIS promotes chromatin regulatory interactions in treatment-resistant cancer cells
Name
Boris_Nature 2019.pdf
Description
Accepted version
Size
7.86 MB
Format
Adobe PDF
Checksum (MD5)
1adbf184bfb6e7d4aa85ed2148a27dc0
Author(s)
Debruyne, David N.
Dries, Ruben
Sengupta, Satyaki
Seruggia, Davide
Gao, Yang
Sharma, Bandana
Huang, Hao
Moreau, Lisa
McLane, Michael
Day, Daniel Sindt
Date Issued
August 2019
Journal
Nature
Publisher
Springer Science and Business Media LLC
Citation
Debruyne, David N. et al. "BORIS promotes chromatin regulatory interactions in treatment-resistant cancer cells." Nature 572, 7771 (August 2019): 676–680 © 2019 The Author(s)
Version
Author's final manuscript
Abstract
The CCCTC-binding factor (CTCF), which anchors DNA loops that organize the genome into structural domains, has a central role in gene control by facilitating or constraining interactions between genes and their regulatory elements1,2. In cancer cells, the disruption of CTCF binding at specific loci by somatic mutation3,4 or DNA hypermethylation5 results in the loss of loop anchors and consequent activation of oncogenes. By contrast, the germ-cell-specific paralogue of CTCF, BORIS (brother of the regulator of imprinted sites, also known as CTCFL)6, is overexpressed in several cancers7–9, but its contributions to the malignant phenotype remain unclear. Here we show that aberrant upregulation of BORIS promotes chromatin interactions in ALK-mutated, MYCN-amplified neuroblastoma10 cells that develop resistance to ALK inhibition. These cells are reprogrammed to a distinct phenotypic state during the acquisition of resistance, a process defined by the initial loss of MYCN expression followed by subsequent overexpression of BORIS and a concomitant switch in cellular dependence from MYCN to BORIS. The resultant BORIS-regulated alterations in chromatin looping lead to the formation of super-enhancers that drive the ectopic expression of a subset of proneural transcription factors that ultimately define the resistance phenotype. These results identify a previously unrecognized role of BORIS—to promote regulatory chromatin interactions that support specific cancer phenotypes.
MIT Department
Massachusetts Institute of Technology. Department of Biology
Terms of Use
Article is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use.
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1038/s41586-019-1472-0
